DexCom Global Regulatory Footprint: G7, Stelo, and Market Access

An FDA regulatory and manufacturing footprint dossier of DexCom, mapping G7 and Stelo OTC clearances, product codes QBJ and SAF, and market access.

Executive Summary

What does DexCom's medical-device regulatory footprint look like, including the FDA 510(k) clearance history of Dexcom G7, G7 15 Day, and the Stelo OTC glucose biosensor, the applicable product codes, and worldwide CGM market access?

DexCom (NASDAQ: DXCM) is the global leader in real-time continuous glucose monitoring, with an FDA clearance genealogy anchored on product code QBJ (prescription integrated CGM, 21 CFR 862.1355) for the Dexcom G7 family and product code SAF (over-the-counter integrated CGM, 21 CFR 862.1355) for the Stelo Glucose Biosensor System, the first glucose biosensor cleared by the FDA for over-the-counter use (cleared for adults March 5, 2024 under K234070, with the Dexcom G7 under K231081 as predicate). Recent milestones include the Dexcom G7 15 Day clearance (2025, overall MARD 8.0% over a 15-day wear — the longest-lasting sensor in the Dexcom portfolio and, by Dexcom's reported MARD, its most accurate) and the Stelo pediatric OTC clearance for children ages 2 and older (June 12, 2026, the first OTC CGM for children), targeting roughly 25 million US adults with Type 2 diabetes who do not use insulin.

What FDA product codes and classification regulation govern Dexcom G7 and Stelo?

To analyze DexCom's regulatory filings, one must understand how the FDA classifies Continuous Glucose Monitoring (CGM) systems. Historically regulated as high-risk Class III devices requiring Premarket Approval (PMA), modern CGMs have been down-classified to Class II (Special Controls) under the iCGM (integrated CGM) pathway.

Both the prescription Dexcom G7 and the over-the-counter (OTC) Stelo system are regulated under the same FDA classification regulation: 21 CFR 862.1355 (Integrated Continuous Glucose Monitoring System). However, they are split into two distinct product codes that govern their intended-use populations, safety controls, and commercial channels:

1. Product Code QBJ: Integrated Continuous Glucose Monitoring System (Prescription)

This product code applies to the Dexcom G7 and the older Dexcom G6 systems.

Intended Use: Indicated for the continuous management of diabetes in patients (including pediatric populations, down to age 2) who require intensive insulin therapy (multiple daily injections or insulin pump integration).
System Integration: Cleared to integrate with Automated Insulin Delivery (AID) systems (such as the Tandem t:slim X2 and Insulet Omnipod 5). This requires high-reliability communication protocols and strict software safety controls since CGM readings directly drive insulin dosing.
Regulatory Pathway: 510(k) Premarket Notification using previous iCGM filings as predicates.

2. Product Code SAF: Integrated Continuous Glucose Monitoring System for Non-Intensive Diabetes Management (Over-the-Counter)

This product code was created specifically for the Stelo Glucose Biosensor System and represents a major regulatory shift.

Intended Use: Indicated for over-the-counter (OTC) use in individuals 18 years and older (expanded to pediatric populations in 2026) who do not use insulin. It is designed to provide glucose trends and alerts, but is explicitly not cleared for making treatment decisions or integrating with insulin pumps.
Safety Thresholds: Because it is sold OTC without physician oversight, the system's software must have built-in guardrails (e.g., clear educational screens, warnings not to adjust medication without consulting a doctor, and no hypoglycemia/hyperglycemia alarms that could cause panic in non-insulin-using populations).
Regulatory Pathway: Cleared via the 510(k) pathway in March 2024 under K234070, using the prescription Dexcom G7 (K231081) as the predicate device; subsequent updates follow the same 510(k) route.

Platform	Product Code	21 CFR Regulation	Device Class	Intended Population	Pump/AID Integration
Dexcom G7	QBJ	21 CFR 862.1355	Class II	Diabetics (prescription required; ages 2+)	Yes (Tandem, Omnipod)
Dexcom Stelo	SAF	21 CFR 862.1355	Class II	Non-insulin-using diabetics & wellness (OTC; ages 2+)	No

FDA Special Controls Requirements for iCGMs (21 CFR 862.1355)

The down-classification of CGMs from Class III to Class II did not mean a loosening of safety standards. Under 21 CFR 862.1355, the FDA established a comprehensive set of Special Controls that any applicant must satisfy.

1. Sensor Performance and Accuracy Limits

The FDA enforces strict limits on sensor accuracy across the entire glycemic range. This is measured against laboratory reference methods (such as the Yellow Springs Instrument or YSI):

MARD Threshold: The system must demonstrate an overall Mean Absolute Relative Difference (MARD) of less than 10%.
Low Glucose Accuracy: The system must maintain high accuracy in the hypoglycemic range (under 70 mg/dL), where sensor lag is most dangerous.
Calibration Stability: If the system is marketed as "factory-calibrated" (no fingersticks required), the manufacturer must validate that the calibration remains stable across the entire wear period.

2. Alarm and Alert Reliability

For prescription systems (QBJ), the FDA mandates specific alarm behaviors:

Urgent Low Alert: A non-mutable alert that triggers when glucose drops below 55 mg/dL.
Predictive Alerts: Algorithms that warn patients before they reach severe hypoglycemia or hyperglycemia.
Alarm Volume: The system must be capable of generating audible alarms even if the user's phone is set to silent or "do not disturb" (override capability).

3. Interoperability and Cybersecurity

Because iCGMs transmit data to third-party devices (insulin pumps, smartwatches, digital health apps), they must comply with rigorous interoperability controls:

Secure BLE Transmission: Data transmitted via Bluetooth Low Energy (BLE) must be encrypted to prevent eavesdropping or signal tampering.
Data Integrity Check: Third-party pumps must verify the integrity of incoming CGM packets before adjusting insulin doses.
Fail-Safe Mode: If the connection between the sensor and the pump is lost, the pump must automatically transition to a safe basal-rate delivery mode.

What is the 510(k) clearance genealogy linking Stelo to the Dexcom G7 predicate?

DexCom's regulatory strategy is built on a step-by-step evolution of its core sensor technology. Rather than redesigning the electrochemical sensor for each product, the company refines the software algorithms, transmitter housings, and applicator mechanisms.

1. The G6 Foundation (De Novo DEN170088)

On March 27, 2018, the FDA granted the De Novo classification request DEN170088 for the Dexcom G6, establishing the first-ever "integrated CGM" (iCGM) classification under 21 CFR 862.1355 and created product code QBJ. This De Novo was a watershed moment because it allowed subsequent iCGMs to be cleared via the 510(k) pathway instead of the lengthy PMA process, provided they met the specific iCGM special controls (such as demonstrating a Mean Absolute Relative Difference, or MARD, of under 10%).

2. The G7 Transition (K213904 / K231081)

The Dexcom G7 was cleared under K213904 in December 2022. The G7 combined the sensor and transmitter into a single, fully disposable wearable patch that was 60% smaller than the G6 and reduced the warm-up time from two hours to 30 minutes. Subsequent clearance K231081 updated the G7 software to enable native integration with the Apple Watch, allowing users to view real-time glucose data on their wrist without having their iPhone nearby. This clearance served as the primary regulatory predicate for the Stelo system.

3. The Stelo 510(k) K234070 Clearance (March 5, 2024)

To launch Stelo as an over-the-counter product, DexCom filed a 510(k) premarket notification, which was cleared under K234070 on March 5, 2024, establishing the new product code SAF for over-the-counter, non-intensive glucose monitoring.

The Predicate Link: The 510(k) used the prescription Dexcom G7 (K231081) as the primary predicate device, demonstrating that the underlying electrochemical sensor and measurement accuracy were identical.
The Difference: The modification was entirely in the software application (stripping out insulin-dosing calculators and high/low alarms, and adding metabolic wellness metrics) and the labeling (changing from prescription-only to over-the-counter).

How did Stelo become the first OTC glucose biosensor, and what is the pediatric clearance?

The clearance of the Stelo Glucose Biosensor System on March 5, 2024, represented a major milestone in consumer digital health. Prior to this, all CGMs in the United States required a prescription, limiting their use to patients with diagnosed diabetes under active medical supervision.

The Consumer Health Expansion

By securing the new product code SAF, DexCom opened up CGM technology to a massive, underserved population:

Type 2 Diabetics Not on Insulin: Approximately 25 million people in the United States live with Type 2 diabetes and manage their condition through diet, exercise, or oral medications (such as Metformin). These patients benefit from seeing how specific meals affect their glucose levels but do not require the complex, alarm-heavy prescription CGMs designed for Type 1 patients.
Prediabetics and Wellness Users: The OTC clearance allows individuals with prediabetes or those interested in metabolic health to purchase sensors directly, bypassing the need for a physician's prescription.

The June 12, 2026 Pediatric OTC Clearance

On June 12, 2026, the FDA granted clearance to expand the Stelo system's labeling to include children and adolescents ages 2 and older who do not use insulin. This was the first-ever OTC CGM clearance for the pediatric population.

Clinical Justification: The clearance was supported by clinical usability data showing that parents and caregivers could safely apply, configure, and interpret the Stelo sensor data without professional medical training.
School and Pediatric Safety: The software was updated to allow parents to share glucose data via remote monitoring apps (Dexcom Share), allowing caregivers to track a child's glucose trends while they are at school.

Biocompatibility and Software Lifecycle Validation (ISO 10993 & IEC 62304)

Wearable sensors require comprehensive engineering validation due to their dual nature: they are subcutaneous invasive medical devices and complex software-driven transmitters.

1. Biocompatibility Validation (ISO 10993)

A CGM sensor probe is inserted through the skin into the subcutaneous tissue, where it remains in contact with interstitial fluid for up to 15 days. Under ISO 10993-1, this requires testing for:

Cytotoxicity (ISO 10993-5): Proving the sensor materials do not cause cellular death or damage.
Sensitization and Irritation (ISO 10993-10): Testing the adhesive patch and housing materials for skin reactions.
Subchronic Toxicity & Implantation (ISO 10993-6): Evaluating local tissue reaction at the subcutaneous insertion site after 15 days of continuous contact.

2. Software Lifecycle Controls (IEC 62304)

The mobile apps (both iOS and Android) are classified as Software in a Medical Device (SiMD). Under IEC 62304, DexCom must document:

Software Risk Assessment: Identifying how a display lag or software crash could lead to missed hypoglycemia events.
Regression Testing: Verifying that minor app store updates (e.g., updating the app for a new iOS release) do not introduce bugs that corrupt the calibration algorithm.
Cybersecurity Patch Management: Establishing a structured process to deploy security updates to the app and transmitter firmware without interrupting glucose monitoring.

Portfolio Comparison: Dexcom G6 vs. G7 vs. G7 15 Day vs. Stelo

To see how DexCom's regulatory genealogy translates into product features, we can construct a comparative matrix of the current and historical portfolio:

Feature	Dexcom G6	Dexcom G7	Dexcom G7 15 Day	Dexcom Stelo
FDA Product Code	QBJ	QBJ	QBJ	SAF
Wear Duration	10 Days	10 Days	15 Days	15 Days
Warm-up Time	2 Hours	30 Minutes	30 Minutes	30 Minutes
MARD (Overall)	9.0%	8.2%	8.0%	9.0%
AID Integration	Yes	Yes	Yes	No
hypoglycemia Alarms	Yes	Yes	Yes	No
Age Range	2 years and older	2 years and older	18 years and older	2 years and older
Commercial Status	Legacy	Active	Active	Active

What is Dexcom G7 15 Day and why does its accuracy and wear time matter?

While Stelo expanded DexCom's footprint into the consumer/OTC space, the company continued to innovate in its core prescription business. In 2025, the FDA cleared the Dexcom G7 15 Day system.

1. Extending Wear Time from 10 to 15 Days

The standard Dexcom G6 and G7 systems were limited to a 10-day wear time. Extending the wear time to 15 days provides significant benefits:

Reduced Patient Burden: Patients only need to apply two sensors per month instead of three, reducing skin irritation at insertion sites.
Lower Annual Cost: Extending wear time reduces the absolute number of sensors required per year, improving reimbursement economics for insurance providers and lowering out-of-pocket costs for cash-paying patients.

2. The Accuracy Benchmark: MARD of 8.0%

A continuous glucose monitor's accuracy is measured by its Mean Absolute Relative Difference (MARD) compared to laboratory reference values. The lower the MARD percentage, the more accurate the sensor.

The Dexcom G7 15 Day achieved an overall MARD of 8.0%, which Dexcom reported as the highest accuracy among cleared CGMs at the time of its 2025 clearance.
This accuracy is critical for integration with Automated Insulin Delivery (AID) systems, where even minor sensor calibration errors can lead to incorrect insulin dosing.

3. Clinical Trial Evidence: MARD by Wear Day

A major hurdle in securing the 15-day clearance was proving that the sensor's accuracy does not degrade over the extended wear period:

Early Days (1–3): Sensors typically experience a "warm-up" stabilization phase. The G7 15 Day clinical data showed a MARD of 8.2% in the first three days.
Mid-Period (4–10): The sensor reaches peak stability, with MARD dropping to 7.8%.
Late Period (11–15): Unlike older sensors that experience "drift" as the glucose-oxidase enzyme degrades, the G7 15 Day maintained a stable MARD of 8.1% through day 15, satisfying the FDA's strict safety standards for extended wear.

Global Manufacturing Footprint: San Diego, Mesa, and Malaysia

To support a global installed base that consumes millions of single-use sensors every week, DexCom has built a robust, highly automated manufacturing footprint.

1. San Diego, California (HQ & Prototyping)

DexCom's headquarters in San Diego houses the core R&D, clinical affairs, and regulatory operations. The facility also operates pilot manufacturing lines used to produce clinical-trial batches and early commercial runs of new platforms.

2. Mesa, Arizona (High-Volume U.S. Manufacturing)

The Mesa facility is DexCom's primary high-volume manufacturing site in the United States. Spanning over 500,000 square feet, this highly automated plant produces sensors and transmitters using robotic assembly lines. The domestic presence in Arizona provides insulation from trade disputes and import tariffs.

3. Penang, Malaysia (EMEA and APAC Supply Hub)

To support international commercialization, DexCom established a major manufacturing facility in Penang, Malaysia.

Global Supply: The Penang plant is designed to supply the European, Middle Eastern, and Asia-Pacific markets, significantly reducing shipping costs and transit times.
Regulatory Audits: The facility is certified under ISO 13485:2016 and undergoes regular audits by EU Notified Bodies and foreign regulators to maintain global market access.

How does DexCom's regulatory footprint compare with Abbott Libre?

The continuous glucose monitoring market is a duopoly dominated by DexCom and Abbott Laboratories. Analyzing the regulatory footprints of both firms reveals contrasting strategies.

Abbott FreeStyle Libre 3 vs. Dexcom G7

Abbott's primary prescription CGM is the FreeStyle Libre 3 (regulated under the same product code QBJ).

Size Advantage: The Libre 3 is extremely small (roughly the size of a U.S. penny) and is applied with a single-piece applicator.
Reimbursement Strategy: Abbott has historically positioned the Libre line as the lower-cost option, securing broad coverage among Medicare and Medicaid populations. DexCom, conversely, has focused on premium features (such as direct-to-Apple Watch streaming and advanced software sharing), though it has closed the cost gap with G7.
A broader look at Abbott's regulatory filings can be found in the Abbott FDA device footprint dossier.

Abbott Libre Rio vs. Dexcom Stelo

Following DexCom's 510(k) clearance of Stelo under the new product code SAF, Abbott quickly responded by securing FDA clearance for its own OTC CGM, the Lingo (for wellness users) and the Libre Rio (for non-insulin-using Type 2 diabetics), both regulated under the same product code SAF.

Intended Use Alignment: Both Libre Rio and Stelo target the same non-insulin Type 2 population.
Software Differences: Lingo focuses heavily on "Lingo Counts" (a gamified metabolic metric), whereas Stelo provides direct, clean glucose readings and target-range indicators.

Abbott Libre Duo: The Next Horizon

The competitive landscape is expanding beyond glucose alone. In 2025, Abbott secured a CE mark in Europe for the Libre Duo, the first dual-analyte sensor that measures both glucose and ketones continuously.

Clinical Utility: Continuous ketone monitoring is a critical safety tool for patients with Type 1 diabetes, providing early warning signs of Diabetic Ketoacidosis (DKA).
Regulatory Status: As of early 2026, the Libre Duo remains under FDA review. DexCom's next-generation G8 platform architecture is designed to support additional analytes beyond glucose over time to counter Abbott's dual-sensor lead.
For details on the dual-sensor, see the Abbott Libre Duo CGM dual glucose ketone sensor review.

For context on where DexCom stands in the broader medtech revenue landscape, see the top medical device companies 2026 revenue rankings.

Safety Records and MAUDE Database Reporting Dynamics

A unique aspect of DexCom's FDA footprint is its massive presence in the FDA's Manufacturer and User Facility Device Experience (MAUDE) database.

The Single Largest Reporter in MAUDE

As documented in the FDA postmarket surveillance trends analysis, DexCom is consistently the single largest reporter of device events in the FDA's database:

2025 Volume: DexCom reported 353,869 events in 2025, representing 12.2% of all MAUDE entries across all medical device manufacturers.
Growth Trend: DexCom's reporting volume grew from 214,142 events in 2020 to over 353,800 in 2025 (a 65% increase).

Contextualizing the Numbers: Malfunctions vs. Injuries

While a third-party analyst might look at these numbers and conclude that DexCom's products have safety issues, a professional regulatory analysis reveals that this volume is a product of two factors:

Consumer Device Scale: Unlike a pacemaker or surgical robot that is implanted in thousands of patients, DexCom's CGMs are worn continuously by millions of patients. A device used by 5 million active users will generate a high volume of reports even if the per-patient error rate is extremely low.
Automated Reporting Programs: Under FDA 21 CFR Part 803 (Medical Device Reporting), manufacturers must report any device malfunction that could lead to injury if it were to recur. Because a CGM is a consumer device, users frequently call customer support to report minor sensor failures, adhesive lifting, or signal dropouts. DexCom's QMS automatically logs these customer complaints and files them as individual MAUDE entries.
No Causality: The vast majority of DexCom's MAUDE reports are classified as Malfunctions (e.g., "sensor failed to insert," "apparent inaccurate reading," "signal loss"). Serious injuries or deaths associated with CGM malfunction are extremely rare.

For a deeper understanding of how these postmarket safety databases operate, see the FDA MAUDE database guide and the Medtronic FDA device footprint comparison.

Frequently Asked Questions (FAQs)

What FDA product code applies to the prescription Dexcom G7 versus the OTC Stelo?

The prescription Dexcom G7 is registered under product code QBJ (Integrated Continuous Glucose Monitoring System). The over-the-counter Stelo Glucose Biosensor System is registered under product code SAF (Integrated Continuous Glucose Monitoring System for Non-Intensive Diabetes Management). Both operate under Class II regulation 21 CFR 862.1355.

When did the FDA clear Stelo as the first over-the-counter glucose biosensor?

The FDA cleared the Stelo Glucose Biosensor System under 510(k) K234070 on March 5, 2024, using the prescription Dexcom G7 (K231081) as predicate. This clearance established the new product code SAF for over-the-counter, non-intensive glucose monitoring.

Is the Dexcom G7 15 Day cleared for children?

No, as of its primary clearances in 2025, the Dexcom G7 15 Day system is cleared only for adults (18 years and older) with diabetes. The standard Dexcom G7 (10-day wear) remains cleared for pediatric populations down to age 2.

What is the MARD of Dexcom G7 15 Day and why does it matter?

The Dexcom G7 15 Day system has an overall Mean Absolute Relative Difference (MARD) of 8.0%, which Dexcom reports as the highest accuracy level among cleared CGMs. That matters for patients who rely on CGM readings to drive automated insulin pumps.

Can the Stelo OTC sensor be used by patients with Type 1 diabetes?

No, the Stelo sensor is explicitly not indicated for patients with Type 1 diabetes or those on intensive insulin therapy. Because Stelo does not feature the low-glucose alarms or pump integration needed to prevent severe hypoglycemia, Type 1 patients must continue to use prescription CGMs under product code QBJ.

Regulatory Compliance and Disclaimers

This regulatory dossier is compiled for educational and competitive-intelligence purposes only based on public FDA disclosures and corporate filings. It does not constitute medical, clinical, or strategic advisory services. For official device classification, indications, and guidelines, consult the FDA Product Classification Database or a certified regulatory affairs professional.